Compare BIO-TECHNE Corp (TECH) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Tesla, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Tesla, Inc. trades at $333.25 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 116.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| TECH | TSLA | |
|---|---|---|
Market Cap | $11.24B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $72.29 | $489.88 |
52-Week Low | $43.31 | $298.16 |
Enterprise Value | $11.32B | $1.28T |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Tesla (TSLA) trades at $332.80, up 1.28% over 24 hours, with a bearish technical signal and high valuation ratios (P/E 306.37, P/S 11.29). Recent Q2 2026 earnings missed expectations, but Q1 and Q4 2025 beat. Revenue declined to $94.83B in 2025, with net income margin at 3.67%. Positive news includes Dutch approval for self-driving software and a potential cheaper EV launch, while competition and delivery misses weigh on sentiment.
Outlook is mixed: analyst consensus price target is $393.87 (18% upside), but high P/E and slowing auto business pose risks. Opportunities lie in AI, robotics, and energy growth, yet execution risks and market volatility require caution. Institutional sentiment is divided, with 40.74% buy ratings but bearish technical indicators near resistance at $333.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
